period in the subsequent three hours. Spontaneous variability in ventricular ectopic beats causes serious problems when using ECG monitoring to evaluate antiarrhythmic drug response in individual patients. The arrhythmias averaged for the entire group remained stable during the recording period. Evaluating antiarrhythmic drugs by examining group response rather than individual patient response minimizes the effect of spontaneous variability. narrowing in a major coronary vessel, or a previous myocardial infarction, or both. Four patients had mitral valve prolapse, one had cardiomyopathy, and five had no clinical evidence for cardiac disease other than the arrhythmias. Previous workup of the latter five patients included normal coronary arteriograms, left ventricular angiograms, and echocardiograms. Thirteen of the 20 patients had experienced episodes of ventricular tachycardia, either as brief 3-10 beat paroxysms or, in four of the 13 patients, as sustained episodes requiring immediate therapy. In addition to these 13 patients, two patients had experienced previous cardiac arrest due to documented ventricular fibrillation. One of these patients had ventricular fibrillation on two separate occasions.
The ECG data for this study were obtained while each patient was hospitalized. The purpose of this hospitalization was the evaluation of antiarrhythmic therapy and the data collected for this study served as a part of a control against which to measure antiarrhythmic drug effects. Sixteen of the 20 patients were hospitalized in the Stanford General Clinical Research Center. Because of the severity of their previous arrhythmias, four were hospitalized in an intermediate care, continuously telemetry-monitored cardiac unit. All antiarrhythmic drugs were discontinued at least five half-lives prior to the recording of the ECG data in this study. No patient had significant abnormalities of hepatic or renal function. All patients had undergone previous cardiac monitoring and most had previously worn ambulatory ECG recording equipment.
All patients had a restful sleep the night before the study. At approximately 8:00 a.m., after a light breakfast, all patients began continuous ECG monitoring using an Avionics ambulatory ECG recorder. During the study, patients were permitted ambulation limited to their rooms and the hallway adjacent to the room. For the 16 patients in the Clinical Research Center, a relaxed atmosphere was provided that was free of many of the usual stresses of a hospital environment.
The first 5 ½/2 hours of the continuous rhythm strip recorded on the ambulatory ECG were analyzed in detail. The total number of ventricular ectopic beats in each minute was determined using a digital computer system.9 Manual checks verified the accuracy of these counts for all patients. To identify and quantify all episodes of ventricular pairs (two consecutive ectopic beats) or salvos (three or more con- secutive ventricular ectopic beats), the entire 51/2 hour ECG rhythm strip was printed and analyzed by visual inspection for all pairs and episodes of ventricular tachycardia. Each patient's rhythm strip was divided into half-hour blocks for arrhythmia data analysis. The initial half-hour was termed the control period and the 10 subsequent half-hour blocks were termed the test period. The total number of ventricular ectopic beats and the number of episodes of pairs and salvos were determined for each of the half-hour blocks (Appendix I). For each patient each half-hour period during the 5-hour test was compared with the half-hour control period for the percent change in total number of ventricular ectopic beats. In addition, it was determined how many halfhour periods contained two consecutive ventricular ectopic beats (pairs) or ventricular tachycardia (three or more ventricular ectopic beats in a row). This method of data analysis simulates conditions of short term antiarrhythmic drug testing with one half-hour of control ECG data and subsequent observation of ECG rhythm for several hours.7 10 However, in the present study no drug was administered after the control period.
SPONTANEOUS VARIATION OF PVCs/ Winkle
To document that each patient's activity level was reasonably constant during each half-hour, the mean heart rate for each half-hour was determined. The mean heart rate for the entire 51/2 hours for all patients was 77.1 I 7.34. The mean individual patient coefficient of variation in heart rates was only 8.6 ± 3.5%. This stability of heart rate suggests that activity level and cardiovascular stress were relatively constant throughout the test period, and changes in these parameters do not account for the observed variation in ventricular ectopic beats.
The statistical evaluation of the total number of ectopic beats in each half-hour compared with control for the group of 20 patients was performed using the Wilcoxon rank sum nonparametric statistical technique.
Results

Variability of the Total Number of Ectopic Beats
Each patient experienced a large spontaneous variation in the total number of ventricular ectopic beats from one halfhour period to the next. When compared with the control half-hour period, these variations ranged from a 99% decline to an 1 100% increase during a single half-hour period. Figure 6 illustrates the percent change in total number of ventricular ectopic beats for each half-hour period compared with the control half-hour period for the entire group of 20 patients. Although individual patients showed considerable spontaneous variability, for the group as a whole there was no statistically significant difference in premature ventricular contraction counts for any one half-hour period compared with the control period. This lack of group variability is explained by the fact that, for any given half-hour period, as many patients showed a spontaneous increase as showed a spontaneous decrease in the total number of ectopic beats. The stability of the group over the five-hour period suggests that there were no systematic trends related to diurnal arrhythmia variation, protocol design, or other factors which might have altered ectopic beat frequency.
Variability of the Occurrence of Pairs and Salvos
Fifteen patients demonstrated paired ectopic beats during the 5½/2 hour study. Ten of these 15 patients had paired premature ventricular contractions during the control half-hour recording period. Five patients manifested this rhythm for the first time during the subsequent 5-hour period. Table 1 shows the number of half-hour periods containing ventricular pairs for the 15 patients who exhibited pairs. If detection of pairs were perfectly reproducible, each patient with pairs should have had 11 half-hour periods containing pairs. However, the data suggest that for many patients with pairs the occurrence varied greatly from one half-hour period to the next. In fact, only three patients showed pairs in each of the 11 half-hour periods.
Five patients demonstrated salvos of ectopic beats during the 51/2 hour study. Two of these five patients had this rhythm during the control half-hour recording and three additional patients showed it for the first time during the subsequent five hours. The number of half-hour periods containing salvos is given in table 1 for the five patients with salvos. As is the case for pairs, the appearance of salvos was highly variable; they occurred during each of the 11 halfhour segments in only one patient.
Measuring Antiarrhythmic Effects in Individual Patients
This spontaneous variation in ventricular ectopic beat frequency would have had considerable impact on the evaluation of antiarrhythmic therapy in many of these individual patients. If a single large dose of an antiarrhythmic drug had been given at the end of the half-hour control, and if one looked for antiarrhythmic effect during the subsequent three hours (the expected time of peak drug plasma concentration), what would have been the conclusions? During the three hours after the control period, 14 of the 20 patients demonstrated a 50% or greater ventricular ectopic beat reduction during at least one half-hour compared with control. Thus, if one defined antiarrhythmic drug responders as those patients with 50% or greater reduction in ectopic beat frequency during a half-hour period, 70% of the patients in this no-drug study would have been classified as responders. Requiring a greater percentage reduction in ectopic beats during a half-hour period provides only a modest improvement (table 2) . Twelve of the 20 patients experienced 60% reduction and seven experienced 80% reduction during at least one half-hour period. Three patients demonstrated at least 90% spontaneous reduction in premature ventricular contractions compared with control during one half-hour period of the first three hours of the test period. No patient had complete suppression for a half-hour period. Simultaneous consideration of complex ventricular arrhythmias did not improve the situation. Considering drug responders as those patients with a 50% reduction in ventricular ectopic beats and elimination of pairs or ventricular tachycardia during the same half-hour period, if these complex rhythms were present during the control period,7 13 of the 20 patients would have been classified as drug responders.
Because for many patients there was great variability in premature ventricular contraction frequency from one halfhour period to the next, and one might expect antiarrhythmic drug effect to be sustained beyond one half-hour, the data were re-analyzed, requiring that each level of ec- topic beat reduction be maintained for either two or three consecutive half-hour periods during the first three hours after control (table 2) . Eight of 20 patients showed 50% premature ventricular contraction reduction that was maintained for two consecutive half-hour periods, and 5 of 20 patients showed 50% reduction that was sustained for three consecutive half-hour periods compared with the control period. Only one patient demonstrated 90% premature ventricular contraction reduction that was sustained for one hour or longer, compared with the control period. This was a patient with sustained bigeminy during the half-hour control period and only occasional premature ventricular contractions during the subsequent five hours. Only by requiring complete ventricular ectopic beat suppression for one halfhour, or nearly complete ventricular ectopic beat suppression (i.e., greater than 90% decline) to be maintained for at least two or three consecutive half-hour periods, is the effect of spontaneous variability reduced to a reasonable level.
Discussion
In recent years, technology has evolved which permits recording and evaluating lengthy ECG strips.6' 9 It is possible to qualitatively and quantitatively grade arrhythmias, and to use ECG recordings to assess the response to antiarrhythmic drugs or other therapeutic and diagnostic interventions. Using these types of data there are two general types of study design which may be used to evaluate antiarrhythmic drug efficacy. One type of study evaluates drug efficacy in one group of patients and compares the data with data obtained in an appropriately matched and separate group of untreated patients.'1-'3 This type of study design frequently randomizes patients to drug or placebo.'4"'l Such a study design eliminates problems with spontaneous arrhythmia variation in individual patients and spontaneous variation which might occur over time for the entire group, such as a spontaneous fall in arrhythmias for all patients after an acute myocardial infarction.
The second general type of study design uses each patient as his own control. A large number of drug studies have followed this design.7 8 10 26-31 It is more difficult to control for spontaneous variation in arrhythmias using this type of study. The present study indicates that any drug or intervention (or as in the present study, a nonintervention) could result in a group of patients with a reduction in arrhythmias, a group of patients with no effect on arrhythmias, and a group of patients with apparent increase in arrhythmias. However, rather than being due to the drug or intervention itself, these groupings might only be due to spontaneous variation in the arrhythmias.
Antiarrhythmic drug studies which use each patient as his own control can avoid this problem by determining group effect rather than responses in individual patients. Such an approach assumes that there are as many patients in whom arrhythmia frequencies are increasing as there are those in whom they are spontaneously decreasing, and therefore one must demonstrate that average arrhythmia frequency for the entire group has not changed over the course of the study. The problems with long-term group trends can be minimized by a cross-over study design. An alternative to group data analysis is to analyze control data for individual patients in order to statistically define levels of arrhythmia decline which are not likely to be due to spontaneous variability alone.
The above comments relate primarily to antiarrhythmic drug trials. However, in the everyday practice of medicine physicians must determine whether or not a given patient is responding to an antiarrhythmic drug. This situation closely parallels the type of drug study where each patient serves as his own control. Baseline ECG recordings of varying length are obtained before drug administration or other intervention and are then continued or repeated after drugs are given. One assumes that the difference in the two ECG recordings is the result of the drug or intervention. If fewer ventricular ectopic beats are seen, one may be inclined to conclude that the drug or intervention has resulted in this reduction. Similarly, if more frequent ventricular ectopic activity or more severe grades of ventricular ectopic beats are seen, one may be inclined to conclude that the drug or intervention is exacerbating the rhythm disturbance.7 10 28 However, the present study illustrates the errors inherent in such reasoning caused by the marked spontaneous variability of ventricular ectopic activity. When evaluating drug effects in patients one must set standards by which it is reasonably certain that one is measuring drug response rather than spontaneous arrhythmia reduction. The data in the present study suggest that for individual patients, by requiring complete disappearance of ectopic beats for a halfhour period or at least 90% suppression in ventricular ectopic beat activity that was maintained for at least one hour, we could be reasonably certain of measuring drug effect, rather than observing spontaneous variation in ventricular beat frequencies.
The findings of this study must not be extrapolated to patients with only infrequent or sporadic ventricular ectopic beats. Our patients were known to have frequent ventricular ectopic beats, and these beats averaged at least one per 1119 VOL 57, No 6, JUNE 1978 minute over the course of the study. Patients with infrequent ventricular ectopic beats might tend to show even more variability than was observed in our patients with frequent ectopic beats, thus making antiarrhythmic drug evaluation even more difficult and less reliable.
One might ask whether longer control ECG recording periods and more recordings during therapy might improve the ability to separate less than nearly complete antiarrhythmic drug effect from spontaneous variation. Within the clinically relevant constraints of the availability of resources, this appears doubtful. In a recent study evaluating therapy with quinidine, propranolol or procainamide, we performed two control 24-hour ambulatory ECGs and maximal exercise treadmill tests one month apart.32 In that study, as in the present study, there was so much spontaneous variability in ventricular ectopic beats that delineation of individual antiarrhythmic drug responders was difficult. Thus, even if 24 hours of ECG data are obtained prior to administering the drug and 24 hours of ECG reading is repeated while the patient is taking the drug, the problem of marked spontaneous variation in ventricular ectopic activity which may mimic or obscure drug effect remains. In that study, however, spontaneous declines in arrhythmias exceeding 90% were uncommon, suggesting that nearly complete arrhythmia suppression can usually separate drug response from spontaneous variation.
While researchers performing antiarrhythmic drug evaluation can determine drug effectiveness by evaluating group drug effect, the clinician charged with the therapy of an individual patient may be left with a sense of confusion. For the present it appears that he must document complete or nearly complete and sustained arrhythmia suppression to be certain he is measuring antiarrhythmic drug effect in a particular patient. 
